One look at the Aducanumab coverage is sufficient to show that journalists have no problem reporting negative news about big companies. Ivermectin isn’t getting positive coverage because there isn’t good evidence that it works. Contrast with the cheap steroids which uncontroversially became a standard treatment because the science showed efficacy.